Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop*

Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921 · see citing works

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop

McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960 · see citing works

Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop*

Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538 · see citing works

Diagnosis of Alzheimer's Disease

Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · see citing works

Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.

(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331 · see citing works

Apolipoprotein E genotyping by one-stage PCR

Wenham, P. R., Price, W. H., & Blundell, G. (1991) · The Lancet · doi:10.1016/0140-6736(91)92823-k · Cited by 1,070 · see citing works

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”

The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 702 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau.

Matsuo, E. S., Shin, R., Billingsley, M., de Voorde, A. V., O'Connor, M., Trojanowski, J., & Lee, V. (1994) · Neuron · doi:10.1016/0896-6273(94)90264-x · Cited by 588 · see citing works

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

Vanmechelen, E., Vanderstichele, H., Davidsson, P., Kerschaver, E. V., Perre, B. V. D., Sjögren, M. J. C., Andreasen, N. C., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 487 · see citing works

Corticobasal degeneration: A clinical study of 36 cases

Rinne, J. O., Lee, M. S., Thompson, P. D., & MARSDEN, C. D. (1994) · Brain · doi:10.1093/brain/117.5.1183 · Cited by 407 · see citing works

Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340 · see citing works

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

Otto, M., Wiltfang, J., Tumani, H., Zerr, I., Lantsch, M., Kornhuber, J., Weber, T., Kretzschmar, H. A., & Poser, S. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00215-2 · Cited by 339 · see citing works

Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease

Arai, H., Terajima, M., Miura, M., Higuchi, S., Muramatsu, T., Machida, N., Seiki, H., Takase, S., Clark, C., Lee, V. M., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380414 · Cited by 314 · see citing works

Neurofibrillary Degeneration in Progressive Supranuclear Palsy and Corticobasal Degeneration

Sergeant, N., Wattez, A., & Delacourte, A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721243.x · Cited by 287 · see citing works

Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease

Kretzschmar, H. A., Ironside, J. W., DeArmond, S. J., & Tateishi, J. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550090125018 · Cited by 287 · see citing works

Linkage Studies of Cholestasis Familiaris Groenlandica/Byler-Like Disease with Polymorphic Protein and Blood Group Markers

Eiberg, H., & Nielsen, I.-M. (1993) · Human Heredity · doi:10.1159/000154139 · Cited by 239 · see citing works

Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their τ isoform distribution and phosphorylation

Delacourte, A., Sergeant, N., Wattez, A., Gauvreau, D., & Robitaille, Y. (1998) · Annals of Neurology · doi:10.1002/ana.410430209 · Cited by 232 · see citing works

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease

Ishiguro, K., Ohno, H., Arai, H., Yamaguchi, H., Urakami, K., Park, J., Sato, K., Kohno, H., & Imahori, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00476-0 · Cited by 175 · see citing works

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients

Kohnken, R. E., Büerger, K., Zinkowski, R. P., Miller, C., Kerkman, D. J., DeBernardis, J. F., Shen, J., Möller, H., Davies, P., & Hampel, H. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01178-2 · Cited by 173 · see citing works

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease

Green, A. J. E., Harvey, R. J., Thompson, E. J., & Rossor, M. N. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00904-5 · Cited by 166 · see citing works

Innervation of Propatagial Musculature in a Flying Squirrel, Glaucomys volans (Rodentia, Sciuridae)

Chickering, J. G., & Sokoloff, A. J. (2008) · Brain Behavior and Evolution · doi:10.1159/000113224 · Cited by 161 · see citing works

Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent Assay

Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Voorde, A., Martin, J.-J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 145 · see citing works

Diagnosis of Alzheimer's Disease

Reisberg, ‌., & Burns, A. S. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004651 · Cited by 126 · see citing works

CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study

Arai, H., Ishiguro, K., Ohno, H., Moriyama, M., Itoh, N., Okamura, N., Matsui, T., Morikawa, Y.-I., Horikawa, E., Kohno, H., et al. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7501 · Cited by 123 · see citing works

Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites

Ishiguro, K., Sato, K., Takamatsu, M., Park, J., Uchida, T., & Imahori, K. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12206-0 · Cited by 84 · see citing works

Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls

Buch, K., Padberg, F., Nolde, T., Teipel, S. J., Stübner, S., Haslinger, A., Schwarz, M., Sunderland, T., Arai, H., Rapoport, S. I., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00845-9 · Cited by 65 · see citing works

A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy

Urakami, K., Mori, M., Wada, K., Kowa, H., Takeshima, T., Arai, H., Sasaki, H., Kanai, M., Shoji, M., Ikemoto, K., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00923-9 · Cited by 59 · see citing works

No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia

Arai, H., Satoh‐Nakagawa, T., Higuchi, M., Morikawa, Y.-I., Miura, M., Kawakami, H., Seki, H., Takase, S., & Sasaki, H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00781-2 · Cited by 52 · see citing works

Tail Proteins in Cerebrospinal Fluid from Patients with Alzheimer's Disease: A Longitudinal Study

Isoe, K., Urakami, K., Shimomura, T., Wakutani, Y., Ji, Y. S., Adachi, Y., & Takahashi, K. (1996) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106874 · Cited by 26 · see citing works

Disturbed consciousness and asthma

Ohrui, T., Yamaya, M., Arai, H., Sekizawa, K., & Sasaki, H. (1997) · The Lancet · doi:10.1016/s0140-6736(05)61602-9 · Cited by 4 · see citing works

Mild cognitive impairment

Gauthier, S. G., Reisberg, ‌., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,920 · see citing works

CSF markers for incipient Alzheimer's disease

Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works

[ ¹⁸ F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · see citing works

Decreased β-Amyloid_1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works

Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

Blennow, K. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.213 · Cited by 487 · see citing works

Post-translational modifications of tau protein in Alzheimer’s disease

Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0221-0 · Cited by 437 · see citing works

Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease: A Comparative Cerebrospinal Fluid Study

Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434 · see citing works

Total and phosphorylated tau protein as biological markers of Alzheimer’s disease

Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389 · see citing works

Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies

Zetterberg, H., & Bendlin, B. B. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0721-9 · Cited by 379 · see citing works

Cerebrospinal Fluid Tau and β-Amyloid: How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses?

Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357 · see citing works

Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease

Otto, M., Wiltfang, J., Cepek, L., Neumann, M., Mollenhauer, B., Steinacker, P., Ciesielczyk, B., Schulz‐Schaeffer, W., Kretzschmar, H. A., & Poser, S. (2002) · Neurology · doi:10.1212/wnl.58.2.192 · Cited by 289 · see citing works

Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231

Büerger, K., Zinkowski, R. P., Teipel, S. J., Tapiola, T., Arai, H., Blennow, K., Andreasen, N., Hofmann‐Kiefer, K., DeBernardis, J. F., Kerkman, D. J., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.8.1267 · Cited by 275 · see citing works

Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review

Minati, L., Edginton, T. L., Bruzzone, M. G., & Giaccone, G. (2008) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317508328602 · Cited by 266 · see citing works

Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 load

Wiltfang, J., Esselmann, H., Bibl, M., Hüll, M., Hampel, H. J., Kessler, H., Frölich, L., Schröder, J., Peters, O., Jessen, F., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04404.x · Cited by 263 · see citing works

Biological markers for therapeutic trials in Alzheimer’s disease

Frank, R., Galasko, D., Hampel, H. J., Hardy, J., de Leon, M. J., Mehta, P. D., Rogers, J., Siemers, E., & Trojanowski, J. Q. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00002-2 · Cited by 252 · see citing works

Insulin Dysfunction InducesIn VivoTau Hyperphosphorylation through Distinct Mechanisms

Planel, E., Tatebayashi, Y., Miyasaka, T., Liu, L., Wang, L., Herman, M., Yu, W. H., Luchsinger, J. A., Wadzinski, B. E., Duff, K., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3949-07.2007 · Cited by 238 · see citing works

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Zetterberg, H., & Blennow, K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00430-x · Cited by 219 · see citing works

Biomarkers of Alzheimer's disease

Craig‐Schapiro, R., Fagan, A. M., & Holtzman, D. M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.003 · Cited by 217 · see citing works

Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?

Mullane, K., & Williams, M. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 212 · see citing works

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

Meredith Jr., J. E., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076523 · Cited by 209 · see citing works

Hereditary Frontotemporal Dementia Caused by <i>Tau</i> Gene Mutations

Van Swieten, J., & Spillantini, M. G. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00052.x · Cited by 195 · see citing works

CSF biomarkers for mild cognitive impairment and early Alzheimer's disease

Andreasen, N., & Blennow, K. (2004) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2004.10.011 · Cited by 192 · see citing works

Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease

Schoonenboom, N. S. M., Pijnenburg, Y. A. L., Mulder, C., Rosso, S. M., van Elk, E. J., van Kamp, G. J., Swieten, J. C. V., & Scheltens, P. (2004) · Neurology · doi:10.1212/01.wnl.0000123249.58898.e0 · Cited by 181 · see citing works

Levels of Nonphosphorylated and Phosphorylated Tau in Cerebrospinal Fluid of Alzheimer's Disease Patients

Hu, Y., He, S., Wang, X., Duan, Q., Grundke, I., Iqbal, K., & Wang, J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62554-0 · Cited by 180 · see citing works

Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition

Leow, A. D., Yanovsky, I., Parikshak, N., Hua, X., Lee, S., Toga, A. W., Jack, C. R., Bernstein, M. A., Britson, P. J., Gunter, J. L., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.004 · Cited by 180 · see citing works

PET amyloid-beta imaging in preclinical Alzheimer's disease

Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 173 · see citing works

CSF biomarkers predict rate of cognitive decline in Alzheimer disease

Kester, M. I., van der Vlies, A. E., Blankenstein, M. A., Pijnenburg, Y. A. L., van Elk, E. J., Scheltens, P., & van der Flier, W. M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd8271 · Cited by 158 · see citing works

CSF biomarkers for mild cognitive impairment

Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151 · see citing works

Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI

Ewers, M., Büerger, K., Teipel, S. J., Scheltens, P., Schröder, J., Zinkowski, R. P., Bouwman, F. H., Schönknecht, P., Schoonenboom, N. S. M., Andreasen, N. C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000286944.22262.ff · Cited by 142 · see citing works

Herpesviruses in brains in Alzheimer's and Parkinson's diseases

Hemling, N., Röyttä, M., Rinne, J. O., Pöllänen, P., Broberg, E., Tapio, V., Vahlberg, T. J., & Hukkanen, V. (2003) · Annals of Neurology · doi:10.1002/ana.10662 · Cited by 142 · see citing works

Combined Plasma Biomarkers for Diagnosing Mild Cognition Impairment and Alzheimer’s Disease

Chiu, M., Yang, S., Horng, H. E., Yang, C., Chen, T., Chieh, J.-J., Chen, H.-H., Chen, T.-C., Ho, C.-S., Chang, S.-F., et al. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400129p · Cited by 136 · see citing works

Core biological marker candidates of Alzheimer?s disease ? perspectives for diagnosis, prediction of outcome and reflection of biological activity

Hampel, H. J., Mitchell, A. J., Blennow, K., Frank, R., Brettschneider, S., Weller, L. J. R., & M�ller, H.-J. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0065-z · Cited by 132 · see citing works

[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3035-4 · Cited by 128 · see citing works

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies

Mitchell, A. J. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.167791 · Cited by 123 · see citing works

Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease

Lewczuk, P., Esselmann, H., Bibl, M., Beck, G., Maler, J., Otto, M., Kornhuber, J., & Wiltfang, J. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:1-2:115 · Cited by 113 · see citing works

Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls

Chou, Y.-Y., Leporé, N., Avedissian, C., Madsen, S. K., Parikshak, N., Hua, X., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Toga, A. W., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.015 · Cited by 117 · see citing works

CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42

Andreasen, N., Sjögren, M. J. C., & Blennow, K. (2003) · The World Journal of Biological Psychiatry · doi:10.1080/15622970310029912 · Cited by 115 · see citing works

Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia

Wiltfang, J., Lewczuk, P., Riederer, P. F., Grünblatt, E., Hock, C., Scheltens, P., Hampel, H. J., Vanderstichele, H., Iqbal, K., Galasko, D. R., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510029786 · Cited by 116 · see citing works

Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years

Stomrud, E., Hansson, O., Minthon, L., Blennow, K., Rosén, I., & Londos, E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.025 · Cited by 114 · see citing works

Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss

Di, J., Cohen, L. S., Corbo, C. P., Phillips, G. R., Idrissi, A. E., & Alonso, A. D. C. (2016) · Scientific Reports · doi:10.1038/srep20833 · Cited by 113 · see citing works

Cerebrospinal Fluid Amyloid ss42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia

de Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.7.755 · Cited by 98 · see citing works

Structural and Quantitative Comparison of Cerebrospinal Fluid Glycoproteins in Alzheimer’s Disease Patients and Healthy Individuals

Sihlbom, C., Davidsson, P., Sjögren, M. J. C., Wahlund, L., & Nilsson, C. L. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9588-x · Cited by 100 · see citing works

The &amp;#x201C;Aged Garlic Extract&amp;#x201D; (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)

Ray, B., B. Chauhan, N., & K. Lahiri, D. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796504664 · Cited by 100 · see citing works

Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease

Maruyama, M., Higuchi, M., Takaki, Y., Matsuba, Y., Tanji, H., Nemoto, M., Tomita, N., Matsui, T., Iwata, N., Mizukami, H., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20494 · Cited by 97 · see citing works

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 97 · see citing works

The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease

Głodzik-Sobańska, L., Pirraglia, E., Bryś, M., Santi, S. D., Mosconi, L., Rich, K. E., Switalski, R., Louis, L. S., Sadowski, M. J., Martiniuk, F. T., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.019 · Cited by 90 · see citing works

Advances in the development of biomarkers for Alzheimer’s disease: from CSF total tau and Aβ1–42 proteins to phosphorylated tau protein

Hampel, H. J., Goernitz, A., & Büerger, K. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00087-x · Cited by 88 · see citing works

Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers

Lewczuk, P., Zimmermann, R., Wiltfang, J., & Kornhuber, J. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0277-y · Cited by 86 · see citing works

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease

Fagan, A. M., & Holtzman, D. M. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.83 · Cited by 85 · see citing works

Tau Protein, Aβ42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

Mollenhauer, B., Cepek, L., Bibl, M., Wiltfang, J., Schulz‐Schaeffer, W., Ciesielczyk, B., Neumann, M., Steinacker, P., Kretzschmar, H. A., Poser, S., et al. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000083178 · Cited by 83 · see citing works

Current state and future directions of neurochemical biomarkers for Alzheimer's disease

de Jong, D., Kremer, B. P. H., Rikkert, M. G. M. O., & Verbeek, M. M. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.320 · Cited by 82 · see citing works

CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia

Stefani, A., Sancesario, G., Pierantozzi, M., Leone, G., Galati, S., Hainsworth, A. H., & Diomedi, M. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.343 · Cited by 80 · see citing works

β‐amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

Wiltfang, J., Esselmann, H., Av, S., Bibl, M., Cepek, L., Steinacker, P., Mollenhauer, B., Büerger, K., Hampel, H. J., Paul, S., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10661 · Cited by 80 · see citing works

Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease

Milà‐Alomà, M., Suárez‐Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 78 · see citing works

Dysregulation of Protein Phosphorylation/Dephosphorylation in Alzheimer′s Disease: A Therapeutic Target

Gong, C., Liu, F., Grundke, I., & Iqbal, K. (2006) · BioMed Research International · doi:10.1155/jbb/2006/31825 · Cited by 79 · see citing works

Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [18F]THK-5117 Positron Emission Tomography

Ishiki, A., Okamura, N., Furukawa, K., Furumoto, S., Harada, R., Tomita, N., Hiraoka, K., Watanuki, S., Ishikawa, Y., Tago, T., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140311 · Cited by 77 · see citing works

Total tau and Phosphorylated tau 181 Levels in the Cerebrospinal Fluid of Patients With Frontotemporal Dementia Due to P301L and G272V tau Mutations

Rosso, S. M., van Herpen, E., Pijnenburg, Y. A. L., Schoonenboom, N. S. M., Scheltens, P., Heutink, P., & Swieten, J. C. V. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1209 · Cited by 77 · see citing works

EFNS guidelines on disease‐specific CSF investigations

Deisenhammer, F., Egg, R., Giovannoni, G., Hemmer, B., Petzold, A., Sellebjerg, F., Teunissen, C., & Tumani, H. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02595.x · Cited by 86 · see citing works

Cerebrospinal fluid tau, Aß, and phosphorylated tau protein for the diagnosis of Alzheimer's disease

Formichi, P., Battisti, C., Radi, E., & Federico, A. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20602 · Cited by 74 · see citing works

Smell identification test as an indicator for cognitive impairment in Alzheimer's disease

Suzuki, Y., Yamamoto, S., Umegaki, H., Onishi, J., Mogi, N., Fujishiro, H., & Iguchi, A. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1161 · Cited by 71 · see citing works

Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid1–42 in the Differentiation between Alzheimer’s Disease and Vascular Dementia

Nägga, K., Gottfries, J., Blennow, K., & Marcusson, J. O. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000066023 · Cited by 71 · see citing works

Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective

Lewczuk, P., Mroczko, B., Fagan, A. M., & Kornhuber, J. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.11.002 · Cited by 70 · see citing works

Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease

Buerger, K., Otto, M., Teipel, S. J., Zinkowski, R., Blennow, K., DeBernardis, J., Kerkman, D., Schröder, J., Schönknecht, P., Cepek, L., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.12.003 · Cited by 70 · see citing works

CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease

Rosenmann, H. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9665-5 · Cited by 68 · see citing works

Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample

Ibach, B., Binder, H., Dragon, M., Poljansky, S., Haen, E., Schmitz, E., Koch, H., Putzhammer, A., Kluenemann, H., Wieland, W. F., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.005 · Cited by 67 · see citing works

Neuropsychological and behavioural correlates of CSF biomarkers in dementia

Engelborghs, S., Maertens, K., Vloeberghs, E., Aerts, T., Somers, N., Mariën, P., & Deyn, P. P. D. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2005.11.002 · Cited by 67 · see citing works

Biochemical Markers and Risk Factors of Alzheimers Disease

Flirski, M., & Sobów, T. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772704 · Cited by 67 · see citing works

Mild cognitive impairment: historical development and summary of research

Golomb, J. B., Kluger, A., & Ferris, S. H. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.4/jgolomb · Cited by 67 · see citing works

Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects

Maccioni, R. B., Manuel Lavados, M., Guillón, M., Mújica, C. L. D., BOSCH, R., FARIAS, G., & FUENTES, P. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.01.011 · Cited by 66 · see citing works

CSF p-Tau levels in the prediction of Alzheimer's disease

Kandimalla, R. J. L., Prabhakar, S. K., Wani, W. Y., Kaushal, A., Gupta, N., Sharma, D. R., Grover, V., Bhardwaj, N., Jain, K., & Gill, K. D. (2013) · Biology Open · doi:10.1242/bio.20135447 · Cited by 65 · see citing works

Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease

Sáez-Valero, J., Fodero, L., Sjögren, M., Andreasen, N., Amici, S., Gallai, V., Vanderstichele, H., Vanmechelen, E., Parnetti, L., Blennow, K., et al. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10599 · Cited by 58 · see citing works

Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature

Zetterberg, H. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12618 · Cited by 57 · see citing works

Neurochemical dementia diagnostics: State of the art and research perspectives

Lewczuk, P., & Wiltfang, J. (2008) · PROTEOMICS · doi:10.1002/pmic.200700703 · Cited by 58 · see citing works

The GSK3β inhibitor, TDZD-8, rescues cognition in a zebrafish model of okadaic acid-induced Alzheimer's disease

Koehler, D., Shah, Z. A., & Williams, F. E. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.10.022 · Cited by 56 · see citing works

Proteomics Analysis of Phosphotyrosyl-Proteins in Human Lumbar Cerebrospinal Fluid

Yuan, X., & Desiderio, D. M. (2003) · Journal of Proteome Research · doi:10.1021/pr025589a · Cited by 55 · see citing works

New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia

del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's &amp; Dementia · doi:10.1002/alz.12643 · Cited by 52 · see citing works

Challenges to demonstrating disease‐modifying effects in Alzheimer's disease clinical trials

Cummings, J. L. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.07.001 · Cited by 54 · see citing works

Clinical significance of fluid biomarkers in Alzheimer’s Disease

Lewczuk, P., Łukaszewicz‐Zając, M., Mroczko, P., & Kornhuber, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00107-0 · Cited by 53 · see citing works

CSF tau and β-amyloid as biomarkers for mild cognitive impairment

Hampel, H., & Blennow, K. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.4/hhampel · Cited by 52 · see citing works

The plant sterol brassicasterol as additional CSF biomarker in Alzheimer’s disease

Vanmierlo, T., Popp, J., Kölsch, H., Friedrichs, S., Jessen, F., Stoffel‐Wagner, B., Bertsch, T., Hartmann, T., Maier, W., von Bergmann, K., et al. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01713.x · Cited by 49 · see citing works

Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease

Sobów, T., Flirski, M., & Liberski, P. P. (2004) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2004-1491 · Cited by 51 · see citing works

CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age

Kester, M. I., Blankenstein, M. A., Bouwman, F. H., van Elk, E. J., Scheltens, P., & van der Flier, W. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0999 · Cited by 50 · see citing works

Neurodegenerative disease biomarkers Aβ1–40, Aβ1–42, tau, and p‐tau181 in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathy

Chen, J., Fears, S. C., Jasinska, A. J., Huang, A., Al‐Sharif, N., Scheibel, K. E., Dyer, T. D., Fagan, A. M., Blangero, J., Woods, R. P., et al. (2018) · Brain and Behavior · doi:10.1002/brb3.903 · Cited by 50 · see citing works

Predicting Alzheimer dementia in mild cognitive impairment patients

Borroni, B., Luca, M. D., & Padovani, A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.023 · Cited by 51 · see citing works

Calcium phosphatase calcineurin influences tau metabolism

Karch, C. M. M., Jeng, A. T., & Goate, A. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.05.003 · Cited by 50 · see citing works

Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease

Erickson, P., Simrén, J., Brum, W. S., Ennis, G. E., Kollmorgen, G., Suridjan, I., Langhough, R. E., Jonaitis, E. M., Hulle, C. A. V., Betthauser, T. J., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.2338 · Cited by 47 · see citing works

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease

Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 46 · see citing works

Neurochemical biomarkers in the differential diagnosis of movement disorders

Mollenhauer, B., & Trenkwalder, C. (2009) · Movement Disorders · doi:10.1002/mds.22510 · Cited by 45 · see citing works

Developing predictive CSF biomarkers—A challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine

Flood, D. G., Marek, G. J., & Williams, M. J. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.021 · Cited by 45 · see citing works

Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases

Otto, M., Lewczuk, P., & Wiltfang, J. (2008) · Methods · doi:10.1016/j.ymeth.2007.06.012 · Cited by 44 · see citing works

Sugar Chains of Cerebrospinal Fluid Transferrin as a New Biological Marker of Alzheimer’s Disease

Taniguchi, M., Okayama, Y., Hashimoto, Y., 北浦美貴, Jimbo, D., Wakutani, Y., Wada‐Isoe, K., Nakashima, K., Akatsu, H., Furukawa, K., et al. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000147479 · Cited by 44 · see citing works

Association of elevated phospho-tau levels with alzheimer-typical 18F-Fluoro-2-Deoxy-D-Glucose positron emission tomography findings in patients with mild cognitive impairment

Fellgiebel, A., Siessmeier, T., Scheurich, A., Winterer, G., Bartenstein, P., Schmidt, L., & Müller, M. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.05.014 · Cited by 44 · see citing works

Cerebrospinal fluid brain‐derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt–Jakob disease

Green, A. J. E. (2002) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2002.t01-2-00427.x · Cited by 41 · see citing works

Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) Myocardial Scintigraphy in Differentiating between Alzheimer's Disease and Dementia with Lewy Bodies

Oide, T., Tokuda, T., Momose, M., Oguchi, K., Nakamura, A., Ohara, S., & Ikeda, S. (2003) · Internal Medicine · doi:10.2169/internalmedicine.42.686 · Cited by 40 · see citing works

Biofluid biomarkers in Alzheimer’s disease and other neurodegenerative dementias

Zetterberg, H., & Bendlin, B. B. (2026) · Nature · doi:10.1038/s41586-025-10018-w · Cited by 40 · see citing works

Biomarkers Predicting Alzheimer's Disease in Cognitively Normal Aging

Shim, Y. S., & Morris, J. C. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.2.60 · Cited by 39 · see citing works

Care for Older People

Ohrui, T., Kubo, H., & Sasaki, H. (2003) · Internal Medicine · doi:10.2169/internalmedicine.42.932 · Cited by 39 · see citing works

Biological Markers in Alzheimer Disease

Neugroschl, J. A., & Davis, K. L. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200211000-00005 · Cited by 36 · see citing works

Dementia Update 2003

Morris, J. C. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200310000-00010 · Cited by 36 · see citing works

Mild cognitive impairment: The dilemma.

Pinto, C., & Subramanyam, A. A. (2009) · PubMed Central · Cited by 35 · see citing works

Cerebrospinal fluid phosphorylated tau protein at serine 199 is a useful diagnostic biomarker in Alzheimer’s disease and mild cognitive impairment

Urakami, K., Arai, H., Itoh, N., Ishiguro, K., Oono, H., Taniguchi, M., Wada‐Isoe, K., Wakutani, Y., Kuzuhara, S., Sasaki, H., et al. (2005) · CRC Press eBooks · doi:10.1201/b14441-26

A large-scale,multi-center study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

伊藤, 伸. (2001)

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease

Ishiguro, K., Ohno, H., Arai, H., Yamaguchi, H., Urakami, K., Park, J., Sato, K., Kohno, H., & Imahori, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00476-0 · Cited by 175 · see citing works

Biomarkers in predicting early in Alzheimer's disease

Galasko, D. R. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82690-1

Value of detection of phosphorylated tau protein in cerebrospinal fluid for diagnosis of Alzheimer's disease

Dong, L. (2007) · Zhonghua laonian xin-nao-xueguanbing zazhi